Zacks: Brokerages Anticipate Genocea Biosciences Inc (GNCA) Will Post Earnings of -$0.14 Per Share

Analysts forecast that Genocea Biosciences Inc (NASDAQ:GNCA) will report earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Genocea Biosciences’ earnings, with estimates ranging from ($0.15) to ($0.13). Genocea Biosciences reported earnings of ($0.54) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 74.1%. The company is expected to announce its next earnings results on Wednesday, August 8th.

According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.74) to ($0.62). For the next fiscal year, analysts expect that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.60). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14).

GNCA has been the subject of several recent analyst reports. Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Cantor Fitzgerald began coverage on Genocea Biosciences in a research note on Monday, March 5th. They issued an “overweight” rating and a $5.00 target price for the company. HC Wainwright set a $5.00 target price on Genocea Biosciences and gave the stock a “buy” rating in a research note on Monday, April 30th. Finally, ValuEngine raised Genocea Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $4.41.

Shares of NASDAQ GNCA opened at $0.93 on Wednesday. Genocea Biosciences has a 12 month low of $0.79 and a 12 month high of $6.78. The company has a quick ratio of 8.06, a current ratio of 8.06 and a debt-to-equity ratio of 1.00. The stock has a market cap of $85.70 million, a PE ratio of -0.47 and a beta of 1.20.

A number of institutional investors and hedge funds have recently modified their holdings of the business. BVF Inc. IL purchased a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $5,250,000. Birchview Capital LP boosted its stake in shares of Genocea Biosciences by 384.6% during the first quarter. Birchview Capital LP now owns 189,000 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 150,000 shares during the period. NEA Management Company LLC purchased a new stake in shares of Genocea Biosciences during the first quarter valued at approximately $26,250,000. Millennium Management LLC purchased a new stake in shares of Genocea Biosciences during the fourth quarter valued at approximately $145,000. Finally, BlackRock Inc. boosted its stake in shares of Genocea Biosciences by 169.1% during the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after purchasing an additional 2,488,540 shares during the period. 61.94% of the stock is owned by institutional investors and hedge funds.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply